Lithium: Sixty years thereafter

Neuropsychobiology

Volumn 62, Issue 1, 2010, Pages 5-7

  Rybakowski, Janusz K ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CCAAT ENHANCER BINDING PROTEIN; CHLORPROMAZINE; CYCLIC AMP; GLYCOGEN SYNTHASE KINASE 3; LITHIUM SALT; PHOSPHATIDYLINOSITOL; PLACEBO; PROTEIN BCL 2; PROTEIN KINASE C; LITHIUM DERIVATIVE; NEUROLEPTIC AGENT;

APOPTOSIS; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; DEPRESSION; DRUG RESPONSE; DRUG TARGETING; EDITORIAL; EVIDENCE BASED MEDICINE; GENE EXPRESSION; GENETIC ASSOCIATION; GOOD CLINICAL PRACTICE; HUMAN; INFLAMMATION; LONG TERM CARE; MANIA; MEDICAL LITERATURE; NONHUMAN; OXIDATIVE STRESS; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; PUBLICATION; PUBLISHING; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; MENTAL DISORDERS;

ANTIPSYCHOTIC AGENTS; HUMANS; LITHIUM COMPOUNDS; MENTAL DISORDERS;

EID: 77951946106     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314304     Document Type: Editorial

References (21)

1. Cade JF: Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 36: 349-352.
2. Delay J, Deniker P, Harl JM: Utilization en thérapeutique psychiatrique d'une phénothiazine d'action centrale élective. Ann Méd Psychol 1952; 110: 112-117.
3. Hartigan GP: The use of lithium salts in affective disorders. Br J Psychiatry 1963; 109: 810-814.
4. Baastrup PC: The use of lithium in manicdepressive psychoses. Compr Psychiatry 1964; 5: 396-408.
5. Baastrup PC, Schou M: Lithium as a prophylactic agent. Its effect against recurrent depression and manic-depressive psychosis. Arch Gen Psychiatry 1967; 16: 162-172.
6. Schou M: Lithium Treatment of Mood Disorders. A Practical Guide, ed 6, revised edition. Basel, Karger, 2006.
7. Grof P: Sixty years of lithium responders. Neuropsychobiology 2010;62:8-16.
8. Grof P: Excellent lithium responders: people whose lives have been changed by lithium prophylaxis; in Birch NJ, Gallicchio VS, Becker RW (eds): Lithium: 50 Years of Psychopharmacology. New Perspectives in Biomedical and Clinical Research. Cheshire, Weidner Publishing Group, 1999, pp 36-51.
9. Rybakowski JK, Chlopocka-Wozniak M, Suwalska A: The prophylactic effect of longterm lithium administration in bipolar patients entering treatment in the 1970s and 1980s. Bipolar Disord 2001; 3: 63-67.
10. Osher Y, Bersudsky Y, Belmaker RH: The new lithium clinic. Neuropsychobiology 2010;62:17-26.
11. Agam G, Bersudsky Y, Berry GT, Moechars D, Lavi-Avnon Y, Belmaker RH: Knockout mice in understanding the mechanism of action of lithium. Biochem Soc Trans 2009; 37: 1121-1125.
12. Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, Schulze TG, Cichon S, Rietschel M, Nöthen MM, Georgi A, Schumacher J, Schwarz M, Abou Jamra R, Höfels S, Propping P, Satagopan J, Detera- Wadleigh SD, Hardy J, McMahon FJ: A genome- wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 2008; 13: 197-207.
13. Moncrieff J: Lithium revisited. A reexamination of the placebo controlled trials of lithium prophylaxis in manic-depressive disorder. Br J Psychiatry 1995; 167: 569-574.
14. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM: Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004; 161: 217-222.
15. Nivoli AMA, Murru A, Vieta E: Lithium: still a cornerstone in the long-term treatment in bipolar disorder? Neuropsychobiology 2010;62:27-35.
16. Bauer M, Adli M, Bschor T, Pilhatsch M, Pfennig A, Sasse J, Schmid, Lewitzka U: Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology 2010;62:36-42.
17. Müller-Oerlinghausen B, Lewitzka U: Lithium reduces pathological aggression and suicidality: a mini-review. Neuropsychobiology 2010;62:43-49.
18. Müller-Oerlinghausen B, Ahrens B, Volk J, Grof P, Grof E, Schou M, Vestergåard P, Lenz G, Simhandl C, Thau K: Reduced mortality of manic-depressive patients in long-term lithium treatment: an international collaborative study by IGSLI. Psychiatry Res 1991; 36: 329-331.
19. Quiroz JA, Machado-Vieira R, Zarate CA, Manji HK: Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 2010;62:50-60.
20. Serretti A, Drago A: Pharmacogenetics of lithium long-term treatment. Focus on initiation and adaptation mechanisms. Neuropsychobiology 2010;62:61-71.
21. Schulze TG, Alda M, Adli M, Akula N, Ardau R, Bui ET, Chillotti C, Cichon S, Czerski P, Del Zompo M, Detera-Wadleigh SD, Grof P, Gruber O, Hashimoto R, Hauser J, Hoban R, Iwata N, Kassem L, Kato T, Kittel- Schneider S, Kliwicki S, Kelsoe JR, Kusumi I, Laje G, Leckband SG, Manchia M, Mac- Queen G, Masui T, Ozaki N, Perlis RH, Pfennig A, Piccardi P, Richardson S, Rouleau G, Reif A, Rybakowski JK, Sasse J, Schumacher J, Severino G, Smoller JW, Squassina A, Turecki G, Young LT, Yoshikawa T, Bauer M, McMahon FJ: The international Consortium on Lithium Genetics (ConLiGen) - an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology 2010;62:72-78.